Stream Companies Celebrates 17th Year on Inc. 5000 Fastest Growing Companies List
August 15, 2024 08:45 ET
|
Stream Companies, LLC
Stream Companies, a premier full-service, integrated, tech-enabled advertising agency, proudly announced today that it has been recognized on the 2024 Inc.
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
August 15, 2024 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
AIQ crowned INC’s 10th fastest growing company, following explosive 16,469% growth
August 14, 2024 10:52 ET
|
Alpine IQ Inc
Alpine IQ has cemented itself as a national leader, earning the title of 10th fastest-growing company in America on Inc.'s Top 5,000 list.
HotelPlanner Ranks No. 978 on the 2024 Inc. 5000
August 13, 2024 09:00 ET
|
Hotelplanner.com
HotelPlanner Ranks No. 978 on the 2024 Inc. 5000 for the 3rd Time in Company History, and 2nd Year in a Row.
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
August 01, 2024 07:05 ET
|
uniQure Inc.
~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of...
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
July 23, 2024 07:05 ET
|
uniQure Inc.
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40...
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
July 09, 2024 07:05 ET
|
uniQure Inc.
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
July 01, 2024 07:05 ET
|
uniQure Inc.
~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~ ~ Genezen to manufacture global...
INC ’24 Denver: Independent National Convention to Match Major Parties with Fall Event
June 04, 2024 11:07 ET
|
United Independents
United Independents announced its re-envisioned programming for INC ‘24 Denver, with new program dates on September 18-20, 2024.
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
June 03, 2024 07:05 ET
|
uniQure Inc.
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...